Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly low-dose versus 3-weekly high-dose cisplatin during primary chemoradiation in sarcopenic head and neck squamous cell carcinoma
2021-002634-16Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisplatin in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Compliance rate to proposed cisplatin scheme and Chemotherapy dose-limiting toxicity. Started Jul 2021; status: active.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-002634-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002634-16.